Beta-Endorphin Needs Its Full Structure to Lower Blood Pressure — Fragments Don't Work
Full beta-endorphin caused naltrexone-reversible hypotension and bradycardia, while N-terminally modified fragments were inactive — the intact opioid-active portion is required for cardiovascular effects.
Quick Facts
What This Study Found
Full beta-endorphin caused naltrexone-reversible hypotension and bradycardia. N-terminally modified fragments were inactive. Beta-endorphin(1-27) induced both hypertensive and hypotensive responses.
Key Numbers
How They Did This
Anesthetized rats received intracerebroventricular injections of beta-endorphin, its fragments, gamma-endorphin, alpha-endorphin fragments, and dynorphin A(1-13) at various doses. Blood pressure and heart rate were continuously recorded.
Why This Research Matters
This shows that the full opioid-active portion of beta-endorphin is needed for its cardiovascular effects. Understanding which parts of the molecule are essential helps in designing peptide-based drugs.
The Bigger Picture
Understanding which parts of beta-endorphin are needed for cardiovascular effects helps design peptide drugs that can separate pain relief from blood pressure changes.
What This Study Doesn't Tell Us
Animal study in anesthetized rats. Anesthesia affects cardiovascular reflexes. Brain injections do not reflect normal physiology. Only acute effects studied.
Questions This Raises
- ?Could modified beta-endorphin analogs provide pain relief without hypotension?
- ?What mechanism underlies beta-endorphin(1-27)'s dual cardiovascular response?
Trust & Context
- Key Stat:
- Full structure required Only intact beta-endorphin with its N-terminal opioid-active domain produced cardiovascular effects; fragments were inactive
- Evidence Grade:
- Preliminary animal study in anesthetized rats. Clear structure-activity relationship demonstrated.
- Study Age:
- Published in 1991. Structure-activity relationships of opioid peptides have been extensively mapped since.
- Original Title:
- Effects of dynorphin A(1-13) and of fragments of beta-endorphin on blood pressure and heart rate of anesthetized rats.
- Published In:
- Canadian journal of physiology and pharmacology, 69(3), 327-33 (1991)
- Authors:
- van Giersbergen, P L(5), de Lang, H(2), de Jong, W(5)
- Database ID:
- RPEP-00217
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why do fragments not work?
The opioid-active portion of beta-endorphin is at the N-terminus (beginning). When this portion is modified or removed, the peptide can no longer activate opioid receptors, eliminating the cardiovascular effects.
What made beta-endorphin(1-27) unusual?
This slightly shortened version produced both a blood-pressure-raising and a blood-pressure-lowering phase, suggesting it activates multiple pathways — possibly both opioid and non-opioid mechanisms.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00217APA
van Giersbergen, P L; de Lang, H; de Jong, W. (1991). Effects of dynorphin A(1-13) and of fragments of beta-endorphin on blood pressure and heart rate of anesthetized rats.. Canadian journal of physiology and pharmacology, 69(3), 327-33.
MLA
van Giersbergen, P L, et al. "Effects of dynorphin A(1-13) and of fragments of beta-endorphin on blood pressure and heart rate of anesthetized rats.." Canadian journal of physiology and pharmacology, 1991.
RethinkPeptides
RethinkPeptides Research Database. "Effects of dynorphin A(1-13) and of fragments of beta-endorp..." RPEP-00217. Retrieved from https://rethinkpeptides.com/research/van-1991-effects-of-dynorphin-a113
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.